A method for the treatment of a disease mediated by a kinase containing a mutation in a region of the protein that binds to or interacts with other cancer agents but does not bind to or interact with the compounds of formula I, with a compound of formula I, for example a mutated kinase selected from c abl, c kit, PDGFR including PDGFR beta and PDGFR alpha, and ErbB family members such as EGFR ErbB1, HER2 ErbB2, ErbB3, and ErbB4, in particular c abl, c kit, PDGFR, members of the Ephrin receptor family including EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphA10, EphB1, EphB2, EphB3, EphB5, EphB6, c Src and kinases of the JAK family such as TYK2, which method comprises administering to a patient in need thereof combination of the invention <a href=https://aviagra.best>does viagra make you bigger than normal</a>
